• Connect with us
    • Information
      • About Us
      • Contact Us
      • Careers
      • Partnerships
      • Advertise With Us
      • Authors
      • Browse Topics
      • Events
      • Disclaimer
      • Privacy Policy
    • Australia
      North America
      World
    Login
    Investing News NetworkYour trusted source for investing success
    • North America
      Australia
      World
    • My INN
    Videos
    Companies
    Press Releases
    Private Placements
    SUBSCRIBE
    • Reports & Guides
      • Market Outlook Reports
      • Investing Guides
    • Button
    Resource
    • Precious Metals
    • Battery Metals
    • Base Metals
    • Energy
    • Critical Minerals
    Tech
    Life Science
    Life Science Market
    Life Science News
    Life Science Stocks
    • Life Science Market
    • Life Science News
    • Life Science Stocks

    Price of Drug Used to Treat Heroin Overdoses on the Rise

    Charlotte McLeod
    Mar. 09, 2015 04:34PM PST
    Life Science Investing

    The Associated Press reported that advocates are worried that the rising price of naloxone could lead to the death of heroin addicts.

    The Associated Press reported that advocates are worried that the rising price of naloxone could lead to the death of heroin addicts. The drug, which is often sold in the US under the brand name Narcan, is used as an antidote to heroin overdoses.

    As quoted in the market news:

    Officials across the country have largely agreed that it makes sense to hand out naloxone to police, families of addicts and drug users themselves, and in some places are now scrambling to negotiate discounts for programs that buy it in bulk for public distribution.

    JSAS HealthCare, a clinic based on the New Jersey shore, began last year training community members to administer the drug and providing it to them with the help of state funds.

    But a price increase late last year means that instead of buying 400 naloxone kits for a little under $21,000 — at $51.50 per kit paid to a third-party distribution company — that’s now enough for only 200, at just under $100 per kit, a negotiated discount that’s $5 cheaper than what he was quoted.

    Jason Shandell, president of Amphastar Pharmaceuticals Inc. (NASDAQ:AMPH), which sells a popular naloxone product, commented:

    Like other companies in the industry, manufacturing costs for our entire portfolio of products, including naloxone, have been steadily increasing due to the continued rise in costs for raw materials, energy, and labor over the recent several years.

    Click here to read the full report from The Associated Press.

    The Conversation (0)

    Go Deeper

    AI Powered

    Sienna Biopharmaceuticals Reports First Quarter 2018 Financial Results

    Pharmadrug

    Pharmadrug

    Latest News

    Lexaria Applauds Eli Lilly's Foundayo Drug Approval

    Lexaria Applauds Eli Lilly's Foundayo Drug Approval

    Seegnal Inc. Establishes Strategic Commercialization Team and Appoints Arx as Investor Relations Advisor

    More News

    Outlook Reports world

    Resource
    • Precious Metals
      • Gold
      • Silver
    • Battery Metals
      • Lithium
      • Cobalt
      • Graphite
    • Energy
      • Uranium
      • Oil and Gas
    • Base Metals
      • Copper
      • Nickel
      • Zinc
    • Critical Metals
      • Rare Earths
    • Industrial Metals
    • Agriculture
    Tech
      • Artificial Intelligence
      • Cybersecurity
      • Gaming
      • Cleantech
      • Emerging Tech
    Life Science
      • Biotech
      • Cannabis
      • Psychedelics
      • Pharmaceuticals

    Featured Life Science Investing Stocks

    More featured stocks

    Browse Companies

    Resource
    • Precious Metals
    • Battery Metals
    • Energy
    • Base Metals
    • Critical Metals
    Tech
    Life Science
    MARKETS
    COMMODITIES
    CURRENCIES